Neurocrine Biosciences (NBIX): Reiterate Top Mid Cap Pick - BMO

September 23, 2016 7:10 AM EDT
Get Alerts NBIX Hot Sheet
Price: $45.05 +0.60%

Rating Summary:
    16 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 49 | New: 20
Trade NBIX Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after the company released abstracts for the American Society of Reproductive Medicine conference (October 15-19).

The analyst stated that the abstracts reinforce elagolix's strong efficacy profile in women with endometriosis, showing significant improvements on endometrial-associated pain, endometrial morphology, and quality of life observed on treatment. He believes the data continues to support approval for elagolix’s low- and high-doses, and his $1.0B peak sales estimate in endometriosis, with an additional blockbuster opportunity in uterine fibroids ($2.7B peak sales).

No change to the price target of $66.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $54.16 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment